^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | decitabine (DNMT inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Excerpt:
...- Somatic TP53 mutation...
Trial ID:
Source:
Title:
Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
Excerpt:
CONTRADICTING EVIDENCE: A total of 113 pts were treated: 73 with decitabine and 40 with azacitidine…On multivariate analysis, age, U2AF1, TP53, and DNMT3A mutations all correlate with poor OS…Mutations had similar effects on OS regardless of HMA used….Low-doses of HMA in pts with lower-risk MDS are safe and can improve outcomes compared to historical data in pts with intermediate or high risk features by the MDA-LRPSS.
DOI:
10.1182/blood-2019-129141
Source:
Title:
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Excerpt:
Response rates were higher among patients with an unfavorable-risk cytogenetic profile than among patients with an intermediate-risk or favorable-risk cytogenetic profile (29 of 43 patients [67%] vs. 24 of 71 patients [34%], P<0.001) and among patients with TP53 mutations than among patients with wild-type TP53 (21 of 21 [100%] vs. 32 of 78 [41%], P<0.001)....Patients with AML and MDS who had cytogenetic abnormalities associated with unfavorable risk, TP53 mutations, or both had favorable clinical responses and robust (but incomplete) mutation clearance after receiving serial 10-day courses of decitabine.
DOI:
10.1056/NEJMoa1605949
Trial ID:
